News & Updates

A Singapore hospital has pioneered a tailored peritoneal dialysis (PD) training program that has yielded a significant reduction in PD-related infections and dropouts among patients with end-stage kidney disease (ESKD).

The proportion of Hong Kong’s population with cardiovascular-kidney-metabolic (CKM) syndrome has increased from 87.8 percent 20 years ago to 90.8 percent in 2024, an ongoing population-based, cross-sectional study of cardiovascular (CV) risk factors and disease prevalence in Hong Kong Chinese (N-CRISPS) has found.

The HeartMate 3 left ventricular assist device (LVAD) can offer a lifeline to patients with severe heart failure, including those with morbid obesity and advanced chronic kidney disease (CKD), medical conditions that carry increased perioperative risks, as suggested in a retrospective cohort study.

Treatment with the investigational agent acoramidis significantly reduced all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at 30 months for patients with transthyretin amyloid cardiomyopathy (ATTR-CM), according to a post hoc analysis of the phase III ATTRibute-CM trial presented at HFSA 2024.

In the treatment of patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), the use of the small interfering ribonucleic acid (siRNA) vutrisiran helps reduce and maintain the stability of NT-proBNP and troponin I—biomarkers associated with increased mortality in this population, as reported in a late-breaking clinical research presentation in HFSA 2024.

Treatment with mavacamten results in improvements in cardiac biomarkers of wall stress and injury, as shown by reduced NT-proBNP and troponin, without sustained left ventricular ejection fraction (LVEF) reductions, according to the preliminary findings of the EMBARK-HFpEF trial.